[Special issue PRO] Considering endpoints for comparative tolerability of cancer treatments using patient report given the estimand framework

John Devin Peipert*, Monique Breslin, Ethan Basch, Melanie Calvert, David Cella, Mary Lou Smith, Gita Thanarajasingam, Jessica Roydhouse

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Regulatory agencies are advancing the use of systematic approaches to collect patient experience data, including patient-reported outcomes (PROs), in cancer clinical trials to inform regulatory decision-making. Due in part to clinician under-reporting of symptomatic adverse events, there is a growing recognition that evaluation of cancer treatment tolerability should include the patient experience, both in terms of the overall side effect impact and symptomatic adverse events. Methodologies around implementation, analysis, and interpretation of “patient” reported tolerability are under development, and current approaches are largely descriptive. There is robust guidance for use of PROs as efficacy endpoints to compare cancer treatments, but it is unclear to what extent this can be relied-upon to develop tolerability endpoints. An important consideration when developing endpoints to compare tolerability between treatments is the linkage of trial design, objectives, and statistical analysis. Despite interest in and frequent collection of PRO data in oncology trials, heterogeneity in analyses and unclear PRO objectives mean that design, objectives, and analysis may not be aligned, posing substantial challenges for the interpretation of results. The recent ICH E9 (R1) estimand framework represents an opportunity to help address these challenges. Efforts to apply the estimand framework in the context of PROs have primarily focused on efficacy outcomes. In this paper, we discuss considerations for comparing the patient-reported tolerability of different treatments in an oncology trial context.

Original languageEnglish (US)
JournalJournal of Biopharmaceutical Statistics
DOIs
StateAccepted/In press - 2024

Keywords

  • Tolerability
  • comparative
  • endpoint
  • estimand
  • oncology
  • patient-reported outcome

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Statistics and Probability
  • Pharmacology

Fingerprint

Dive into the research topics of '[Special issue PRO] Considering endpoints for comparative tolerability of cancer treatments using patient report given the estimand framework'. Together they form a unique fingerprint.

Cite this